Olafur S. Palsson

ORCID: 0000-0002-4480-3708
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Gastrointestinal motility and disorders
  • Infant Health and Development
  • Gastroesophageal reflux and treatments
  • Complementary and Alternative Medicine Studies
  • Pain Management and Placebo Effect
  • Diet and metabolism studies
  • Music Therapy and Health
  • Pelvic floor disorders treatments
  • Helicobacter pylori-related gastroenterology studies
  • Pathogenesis and Treatment of Hiccups
  • Congenital gastrointestinal and neural anomalies
  • Diverticular Disease and Complications
  • Mindfulness and Compassion Interventions
  • Pediatric Pain Management Techniques
  • Therapeutic Uses of Natural Elements
  • Eosinophilic Esophagitis
  • Child Nutrition and Feeding Issues
  • Psychosomatic Disorders and Their Treatments
  • Respiratory and Cough-Related Research
  • Migraine and Headache Studies
  • Microscopic Colitis
  • Intestinal and Peritoneal Adhesions
  • Digestive system and related health
  • Health, psychology, and well-being
  • Dysphagia Assessment and Management

University of North Carolina at Chapel Hill
2016-2025

Motility (United States)
2015-2025

Rome Foundation
2021-2024

University of North Carolina Health Care
2007-2023

Frontier Agriculture (United Kingdom)
2023

AT Sciences (United States)
2016

Northwestern University
2015

University Gastroenterology
1997-2013

Group Health Cooperative
2003-2007

University of Washington
2003-2007

Background & AimsAlthough functional gastrointestinal disorders (FGIDs), now called of gut-brain interaction, have major economic effects on health care systems and adversely affect quality life, little is known about their global prevalence distribution. We investigated the factors associated with 22 FGIDs, in 33 countries 6 continents.MethodsData were collected via Internet 24 countries, personal interviews 7 both 2 using Rome IV diagnostic questionnaire, III irritable bowel syndrome...

10.1053/j.gastro.2020.04.014 article EN cc-by-nc-nd Gastroenterology 2020-04-12

This prospective, randomized controlled trial explored the feasibility and efficacy of a group program mindfulness training, cognitive-behavioral technique, for women with irritable bowel syndrome (IBS). The technique involves training in intentionally attending to present-moment experience non-judgmental awareness body sensations emotions.Seventy-five female IBS patients were randomly assigned eight weekly one half-day intensive sessions either (MG) or support (SG). Participants completed...

10.1038/ajg.2011.184 article EN The American Journal of Gastroenterology 2011-06-21

Epidemiological studies support an association of self-defined constipation with fiber and physical activity, but not liquid intake. The aims this study were to assess the prevalence associations dietary intake constipation.Analyses based on data from 10,914 adults (≥20 years) 2005-2008 cycles National Health Nutrition Examination Surveys. Constipation was defined as hard or lumpy stools (Bristol Stool Scale type 1 2) "usual most common stool type." Dietary total moisture content obtained...

10.1038/ajg.2013.73 article EN The American Journal of Gastroenterology 2013-04-09

Our aim was to evaluate the association between visceral hypersensitivity and GI symptom severity in large cohorts of patients with functional disorder (FGID) adjust for psychological factors general tendency report symptoms.We included five FGIDs (IBS or dyspepsia; n=1144), who had undergone sensitivity testing using balloon distensions (gastric fundus, descending colon rectum) completed questionnaires assess severity, non-GI somatic symptoms, anxiety depression. Subjects were divided into...

10.1136/gutjnl-2016-312361 article EN Gut 2017-01-19

The population prevalence of Rome IV-diagnosed functional gastrointestinal disorders (FGIDs) and their cumulative effect on health impairment is unknown.An internet-based cross-sectional survey was completed by 5,931 6,300 general adults from three English-speaking countries (2100 each USA, Canada, UK). Quota-based sampling used to generate demographically balanced representative samples with regards age, sex, education level. enquired for demographics, medication, surgical history,...

10.1038/ajg.2017.421 article EN The American Journal of Gastroenterology 2017-11-14

Summary Aim To provide estimates of actual costs to deliver health care patients with functional bowel disorders, and assess the cost impact symptom severity, recency onset, satisfaction treatment. Methods We enrolled 558 irritable (IBS), 203 constipation, 243 diarrhoea 348 abdominal pain from primary gastroenterology clinics at a maintenance organization within weeks visit. Costs were extracted administrative claims. Symptom treatment out‐of‐pocket expenses assessed by questionnaires....

10.1111/j.1365-2036.2007.03370.x article EN Alimentary Pharmacology & Therapeutics 2007-05-11

BACKGROUND Comorbid nongastrointestinal symptoms account for two-thirds of excess health-care costs in irritable bowel syndrome (IBS). OBJECTIVES To determine whether IBS patients are at greater risk specific comorbid disorders versus showing a general tendency to overreport symptoms; with inflammatory disease (IBD) show patterns comorbidity similar IBS; is explained by psychiatric disease; and occurs all patients. METHODS All 3,153 health maintenance organization diagnosis 1994–1995 were...

10.1111/j.1572-0241.2007.01540.x article EN The American Journal of Gastroenterology 2007-12-01

The Rome III classification system treats functional constipation (FC) and irritable bowel syndrome with (IBS-C) as distinct disorders, but this distinction appears artificial, the same drugs are used to treat both. This study's hypothesis is that FC IBS-C defined by not entities.In all, 1,100 adults a primary care visit for 1,700 age- gender-matched controls from health maintenance organization completed surveys 12 months apart; 66.2% returned first questionnaire. criteria identified 231...

10.1038/ajg.2010.200 article EN The American Journal of Gastroenterology 2010-05-25

Patient education improves clinical outcomes in patients with chronic illness, but little is known about the needs of IBS. OBJECTIVES The objective this study was to identify: (1) perceptions IBS; (2) content areas where feel insufficiently informed, i.e., “knowledge gaps” diagnosis, treatment options, etiology, triggers, prognosis, and role stress; (3) whether there are differences related items 1 2 among clinically significant subgroups. METHODS IBS-Patient Education Questionnaire...

10.1111/j.1572-0241.2007.01254.x article EN The American Journal of Gastroenterology 2007-05-09

Omega-3 and n-6 fatty acids are biosynthetic precursors to lipid mediators with antinociceptive pronociceptive properties. We conducted a randomized, single-blinded, parallel-group clinical trial assess biochemical effects of targeted alteration in dietary n-3 for treatment chronic headaches. After 4-week preintervention phase, ambulatory patients daily headache undergoing usual care were randomized 1 2 intensive, food-based 12-week interventions: high plus low (H3-L6) intervention, or (L6)...

10.1016/j.pain.2013.07.028 article EN Pain 2013-07-22

<b>Objective:</b> The aim was to determine whether lower visceral pain thresholds in irritable bowel syndrome (IBS) primarily reflect physiological or psychological factors. <b>Methods:</b> Firstly, 121 IBS patients and 28 controls underwent balloon distensions the descending colon using ascending methods of limits (AML) assess urge thresholds. Secondly, sensory decision theory analysis used separate from components perception: neurosensory sensitivity (p(A)) measured by ability discriminate...

10.1136/gut.2006.117390 article EN Gut 2007-04-05

Recent data suggest a role for the intestinal microbiota in pathogenesis of functional bowel disorders (FBDs). Probiotic studies FBDs generated inconsistent results suggesting strain-specific and product-specific effect.To investigate clinical efficacy Lactobacillus acidophilus NCFM (L-NCFM) Bifidobacterium lactis Bi-07 (B-LBi07) nonconstipation FBDs.A double-blind, placebo-control trial probiotic bacterias L-NCFM B-LBi07 twice day (2×10(11) CFU/d) versus placebo over 8 weeks. Primary...

10.1097/mcg.0b013e31820ca4d6 article EN Journal of Clinical Gastroenterology 2011-03-24
Coming Soon ...